Transthoracic vs Transbronchial Radiofrequency Ablation for Lung Cancer
The aim of this study is to investigate the efficacy and safety of transthoracic versus transbronchial ablation in the treatment of early stage peripheral lung cancer.
| Condition(s) | Lung Cancer Stage IA |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The aim of this study is to investigate the efficacy and safety of transthoracic versus transbronchial ablation in the treatment of early stage peripheral lung cancer. |
| Who can participate | Inclusion Criteria: 1. Age greater than 18 years. 2. Primary peripheral lung cancer diagnosed by pathology and pre-procedure staging examination suggesting clinical stage T1N0M0, stage IA (including postoperative new and multiple primary). 3. The proposed ablation lesion was evaluated for feasibility of CT and bronchoscopy-guided ablation treatment. 4. Consent to initial ablation therapy is given after assessment of unsuitability for surgery or refusal of surgery and signed informed consent form. Exclusion Criteria: 1. Patients with platelets \<50×109/L, severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term. 2. Patients with severe pulmonary fibrosis and pulmonary arterial hypertension. 3. Infectious and radioactive inflammation around the lesion, |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Shanghai Chest Hospital |
| Locations | Shanghai, Shanghai Municipality, China |
| Start date | 2024-01-04 |
| NCT ID | NCT06503744 |
| Official listing | https://clinicaltrials.gov/study/NCT06503744 |